The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
Author:
Affiliation:
1. Department of Oncology; Zhujiang Hospital of Southern Medical University; Guangzhou China
2. Department of Respiratory Medicine; Shanghai Tenth People's Hospital; Tongji University; Shanghai China
Funder
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
Publisher
Wiley
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1768/fullpdf
Reference50 articles.
1. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clinic Proceedings,2008
2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N Engl J Med,2014
3. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013
4. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study;Soria;Lancet,2017
5. Targeted therapies for the treatment of non-small-cell lung cancer: monoclonal antibodies and biological inhibitors;Silva;Hum Vaccin Immunother,2017
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Invasive Diagnostic Procedures from Bronchoscopy to Surgical Biopsy—Optimization of Non-Small Cell Lung Cancer Samples for Molecular Testing;Medicina;2023-09-27
2. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta‐analysis;Cancer Medicine;2023-04-05
3. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer;Journal of Thoracic Disease;2023-04
4. Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis;International Journal of Molecular Sciences;2023-01-23
5. Ligand-based pharmacophore modelling in search of novel anaplastic lymphoma kinase inhibitors;Results in Chemistry;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3